Groupe d'Etude en Oncologie du Quebec

Title	A Pilot Study of Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in Rectal Cancer Patients.
Protocole ID	Morpheus study (no surgery)
ClinicalTrials.gov ID	NCT03051464
Cancer Type(s)	Colon and Rectum
Phase
Stage
Study Type	Clinical
Drug
Institution	CISSS DE L'OUTAOUAIS HOPITAL DE GATINEAU 909 Boulevard La Vérendrye, Gatineau, QC, J8P 7H2
City
Principal Investigator	Dr. Robert Archambault
Coordinator	Céline Roy 819-966-6100 poste 3669
Status	Recruiting
Activation Date
Eligibility Criteria	Rectal cancer patients, clinically staged as T2-T3 by MRI or endoscopic/trans-rectal ultrasound Rectal cancer staged as N0-N1 by MRI or EUS/TRUS No metastatic lesion Rectal tumor occupying less than half of the circumference Tumor less than 5 cm on its largest dimension Tumor located at less than 10 cm from the anal verge Tumor penetration less than 5 mm in the mesorectal fat Tumor accessible for brachytherapy Lumen accessible for colonoscopy Patient should be a suitable candidate for brachytherapy and chemotherapy Older than 18 years of age Adequate birth control measures in women of childbearing potential Written informed consent
Exclusion Criteria	Patients with previous pelvic radiation Evidence of distant metastasis Extension of malignant disease to the anal canal Tumors staged as T4 Tumors larger than 5 cm in length

Groupe d'étude en oncologie du Québec